TPA sales at wholesaler level
Bergen-Brunswig sold 2,329 vials of Genentech's Activase in September, the lowest monthly volume since March when the distributor sold 2,215 vials. Bergen's December sales of TPA were its highest at 4,696 vials: sales tailed to 3,897 vials in April, dropping to 2,584 vials in August. In terms of sales to patients, and based on an average patient cost of approximately $ 2,300 per vial, Bergen Brunswig's sales of TPA this year through September were approximately $ 67 mil.
You may also be interested in...
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.